Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration

Retina

Volumn 32, Issue 5, 2012, Pages 967-971

  Hosseini, Hamid ^a   Lotfi, Mehrzad ^b   Esfahani, Mina Heidari ^b   Nassiri, Nariman ^c   Khalili, Mohammad Reza ^a   Razeghinejad, Mohammad Reza ^a   Nouri Mahdavi, Kouros ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Vanak Eye Surgery Center   (Iran)

^d JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CENTRAL RETINA ARTERY OCCLUSION; CILIARY ARTERY; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DRUG EFFECT; EYE; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; MACHINE; MALE; NEOVASCULARIZATION (PATHOLOGY); PROSPECTIVE STUDY; RETINA; RETINA BLOOD FLOW; RETINA MACULA AGE RELATED DEGENERATION; SINGLE DRUG DOSE; ULTRASOUND;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CILIARY ARTERIES; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; RETINAL ARTERY; ULTRASONOGRAPHY, DOPPLER, COLOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84860839218     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822c28d6     Document Type: Article

References (34)

1. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Oph-thalmol 2007;18:502-508. (Pubitemid 351339405)
2. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Oph-thalmol 2008;92:1636-1641.
3. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-165.
4. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010;117: 298-302.
5. Jeganathan VSE, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol 2009;20:223-225.
6. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye 2009;24:816-824.
7. Furino C, Boscia F, Cardascia N, et al. Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2010;9:1-2.
8. Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2009;247:1707-1710.
9. Hosseini H, Razeghinejad MR. Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. J Neuro-ophthalmol 2009;29:160-161.
10. Huang ZL, Lin KH, Lee YC, et al. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica 2009;224:86-89.
11. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to nonischaemic central retinal vein occlusion. Acta Ophthalmol 2008;86:925-927.
12. Mansour AM, Bynoe LA, Welch JC, et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 2010; 88:730-735.
13. Yokoyama K, Choshi T, Kimoto K, et al. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol 2008;86:927-928.
14. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349. (Pubitemid 44702055)
15. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2010.
16. Mendrinos E, Mangioris G, Papadopoulou D, et al. One year results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2009.
17. Papadopoulou DN, Mendrinos E, Mangioris G, et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:1755-1761.
18. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema Acta Ophthalmol 2008;86:365-371.
19. Sato E, Feke GT, Appelbaum EY, et al. Association between systemic arterial stiffness and age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2006;244:963-971. (Pubitemid 44184501)
20. Bonnin P, Pournaras JAC, Lazrak Z, et al. Ultrasound assessment of short term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age related macular degeneration. Acta Ophthalmol 2010;88:641-645.
21. Mete A, Saygili O, Bayram M, Bekir N. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age related macular degeneration. J Clin Ultrasound 2010;38:66-70.
22. Baxter GM, Williamson T. Color Doppler imaging of the eye: normal ranges, reproducibility, and observer variation. J Ultrasound Med 1995;14:91-96.
23. Lieb WE, Flaharty PM, Ho A, Sergott RC. Color Doppler imaging of the eye and orbit: a synopsis of a 400 case experience. Acta Ophthalmol 1992;70:50-54.
24. Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv Ophthalmol 1996;40:255-267. (Pubitemid 26046205)
25. Lieb W, Cohen S, Merton D, et al. Color Doppler imaging of the eye and orbit: technique and normal vascular anatomy. Arch Ophthalmol 1991;109:527-531.
26. Harris A, Joos K, Kay M, et al. Acute IOP elevation with scleral suction: effects on retrobulbar haemodynamics. Br J Ophthalmol 1996;80:1055-1059. (Pubitemid 27010839)
27. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic ret-inopathy. Ophthalmology 2006;113:1695.
28. Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cys-toid macular edema. J Am Assoc Pediatr Ophthalmol Strabismus 2009;13:400-402.
29. Liu MH, Jin H, Floten HS, et al. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg 2002;73:819-824. (Pubitemid 34188321)
30. Donati G, Pournaras C, Munoz J, et al. Nitric oxide controls arteriolar tone in the retina of the miniature pig. Investig Ophthalmol Vis Sci 1995;36:2228-2237.
31. Wei W, Chen ZW, Yang Q, et al. Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery. Vascul Pharmacol 2007;46:253-259. (Pubitemid 46124089)
32. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circul Physiol 2006;290: H547-559.
33. Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult micro-vasculature. Am J Physiol Heart Circul Physiol 2006;290: H560-576.
34. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Investig 2006;116:2610-2618.